Skip to main content
. 2014 Mar 3;2(1):e00028. doi: 10.1002/prp2.28

Table 4.

Number of adverse events reported in the FDA-AERS database and proportional reporting ratio

ADRs (8 months) October 2011–June 2012 Glyburide/Glibenclamide Glimepiride Tolbutamide Repaglinide Nateglinide All drugs
Muscle atrophy (N) 4 c (PRR = 12) (Chi Q = 0.3.) 0 0 0 0 373
Total (N) 1460 945 34 337 83 1,697,582

ADR, adverse drug reactions; PRR, proportional reporting ratio; c, indicates concomitant drug treatment.